Breaking News
FONT-SIZE Plus   Neg
Share SHARE

Yahoo! To Axe About 2K Jobs - Quick Facts

RELATED NEWS
Trade YHOO now with 

Yahoo! (YHOO: Quote) confirmed that it is taking important steps in reshaping the company for the future, and has identified key parts of the business, a select group of core businesses, the platforms that support those core businesses, and the data that drives deep personalization for users and ROI for advertisers, where it would intensify efforts and redeploy resources worldwide, entirely focusing on enhancing shareholder value.

Therefore, the company would start informing employees about these changes, and as part of that effort, around 2,000 people would be notified of job elimination or phased transition. The company, through its restructuring efforts, plans to grow by responding more quickly to customer needs and competing more effectively in areas where it can win.

Further, Yahoo! expects to realize nearly $375 million of annualized savings upon the close of all employee transitions. The company now sees to recognize the majority of an estimated $125 million - $145 million pretax cash charge relating to employee severance in its second quarter financial results.

Click here to receive FREE breaking news email alerts for Yahoo! Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Proctor and Gamble (PG) has sold two of its soap brands to European consumer products giant Unilever (UN). Cincinnati-based P&G says the sale includes the global Camay brand, the Zest brand outside of North America and its Talisman manufacturing plant in Mexico. The plant employs approximately... Dish Network is no longer carrying Fox News in yet another dispute for the television provider. Fox News, which changed the face of cable news with its ardent advocacy of conservative issues, went dark Sunday, replaced on Dish by The Blaze, Glen Beck's new right-leaning channel. Fox Business channel... Swiss drug maker Roche Holding said a late-stage trial of its breast cancer drug Kadcyla did not provide superior results compared with an existing therapy.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.